Biblio

33557 resultats trouvés
Filtres: Filter is   [Clear All Filters]
A
Amedro F, Matrion B.  2014.  The Albian Stage in its type area, the Aube (France): a synthesis in a global sedimentary context. CARNETS DE GEOLOGIE. 14:69-128.
Bernardi M, Angeli P, Claria J, Moreau R, Gines P, Jalan R, Caraceni P, Fernandez J, Gerbes AL, O'Brien AJ et al..  2020.  Albumin in decompensated cirrhosis: new concepts and perspectives. GUT. 69:1127-1138.
Thevenot T., Bureau C., Oberti F., Anty R., Louvet A., Plessier A., Rudler M., Heurgue-Berlot A., Rosa I., Talbodec N. et al..  2014.  ALBUMIN INFUSION FOR BACTERIAL INFECTIONS OTHER THAN SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: A MULTICENTER RANDOMIZED CONTROLLED STUDY (ALB-CIRINF STUDY). JOURNAL OF HEPATOLOGY. 60:S29.
Garioud A, Cadranel J-F, Pauwels A, Nousbaum J-B, Thevenot T, Dao T, Louvet A, Sogni P, Talbodec N, Antonini TM et al..  2017.  Albumin Use in Patients With Cirrhosis in France: Results of the ``ALBU-LIVE'' Survey A Case for Better EASL Guidelines Diffusion and/or Revision. JOURNAL OF CLINICAL GASTROENTEROLOGY. 51:831-838.
Gobeaux F, Bizeau J, Samson F, Marichal L, Grillo I, Wien F, Yesylevsky SO, Ramseyer C, Rouquette M, Lepetre-Mouelhi S et al..  2020.  Albumin-driven disassembly of lipidic nanoparticles: the specific case of the squalene-adenosine nanodrug. NANOSCALE. 12:2793-2809.
Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, Prabhu S, Stub D, Azzopardi S, Vizi D et al..  2020.  Alcohol Abstinence in Drinkers with Atrial Fibrillation. NEW ENGLAND JOURNAL OF MEDICINE. 382:20-28.
Ursic-Bedoya J, Dumortier J, Altwegg R, Belkacemi M, Vanlemmens C, Dharancy S, Besch C, Shili-Masmoudi S, Francoz C, Boillot O et al..  2021.  Alcohol Consumption the Day of Liver Transplantation for Alcohol-Associated Liver Disease Does Not Affect Long-Term Survival: A Case-Control Study. LIVER TRANSPLANTATION. 27:34-42.
Kastler A, Cadel G, Comte A, Gory G, Piccand V, Tavernier L, Kastler B.  2014.  Alcohol percutaneous neurolysis of the sphenopalatine ganglion in the management of refractory cranio-facial pain. NEURORADIOLOGY. 56:589-596.
Latino-Martel P, Cottet V, Druesne-Pecollo N, Pierre FHF, Touillaud M, Touvier M, Vasson M-P, Deschasaux M, Le Merdy J, Barrandon E et al..  2016.  Alcoholic beverages, obesity, physical activity and other nutritional factors, and cancer risk: A review of the evidence. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 99:308-323.
Dupuis-Girod S., Fargeton A-E, Paez C., Ambrun A., Decullier E., Roux A., Breant V, Beni K., Riviere S., Lacombe P. et al..  2015.  Alegori study: efficacy of a bevacizumab nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT). A randomized trial against placebo with dose selection. ANGIOGENESIS. 18:538-539.
O. Fernandez F, Hartung H-P, Laganke C., Margolin D.H, Kasten L., Moreau T., Giovannoni G..  2015.  Alemtuzumab has a durable effect on disability improvement in treatment-naive patients with relapsing-remitting multiple sclerosis: a 4-year follow-up of CARE-MS I. EUROPEAN JOURNAL OF NEUROLOGY. 22:824.
Coles A, Giovannoni G, Moreau T, Havrdova E, Margolin D, Kasten L, Singer B.  2015.  ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 86
Moreau T., Margolin D.H, Kasten L., Singer B., Investigators CARE-MSII.  2014.  Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: 3-year follow-up of CARE-MS II. MULTIPLE SCLEROSIS JOURNAL. 20:86.
R. Gonzalez A, Moreau T., Cohen J.A, Giovannoni G., Margolin D.H, Kasten L., Havrdova E..  2015.  Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients with inadequate efficacy response to prior therapy: 4-year follow-up of CARE-MS II. EUROPEAN JOURNAL OF NEUROLOGY. 22:614.
Moreau T., Margolin D.H, Kasten L., Singer B., Investigators CARE-MSII.  2014.  Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: 3-year follow-up of CARE-MS II. MULTIPLE SCLEROSIS JOURNAL. 20:86.
R. Gonzalez A, Moreau T., Cohen J.A, Giovannoni G., Margolin D.H, Kasten L., Havrdova E..  2015.  Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients with inadequate efficacy response to prior therapy: 4-year follow-up of CARE-MS II. EUROPEAN JOURNAL OF NEUROLOGY. 22:614.
Nkeck JRene, Tsafack EElisee, Ndoadoumgue ALaetitia, Endomba FTeddy.  2020.  An alert on the incautious use of herbal medicines by sub-Saharan African populations to fight against the COVID-19. PAN AFRICAN MEDICAL JOURNAL. 35:26.
Fertouna-Bellakhal M, Dhib A, Fathalli A, Bellakhal M, Chomerat N, Masseret E, Laabir M, Turki S, Aleya L.  2015.  Alexandrium pacificum Litaker sp nov (Group IV): Resting cyst distribution and toxin profile of vegetative cells in Bizerte Lagoon (Tunisia, Southern Mediterranean Sea). HARMFUL ALGAE. 48:69-82.
Trincal V, Lanari P.  2016.  Al-free di-trioctahedral substitution in chlorite and a ferri-sudoite end-member. CLAY MINERALS. 51:675-689.
Ushirobira R, Perruquetti W, Mboup M.  2016.  An algebraic continuous time parameter estimation for a sum of sinusoidal waveform signals. INTERNATIONAL JOURNAL OF ADAPTIVE CONTROL AND SIGNAL PROCESSING. 30:1689-1713.
Blanc J, Dubouloz A.  2018.  Algebraic models of the Euclidean plane. EPIJOURNAL DE GEOMETRIE ALGEBRIQUE. 2:14.
Dubouloz A, Mangolte F.  2021.  Algebraic models of the line in the real affine plane. GEOMETRIAE DEDICATA. 210:179-204.
Dubouloz A, Mangolte F.  2021.  Algebraic models of the line in the real affine plane. GEOMETRIAE DEDICATA. 210:179-204.
Massuyeau G, Turaev V.  2017.  ALGEBRAS, BRACKETS, AND BIBRACKETS. BRACKETS IN THE PONTRYAGIN ALGEBRAS OF MANIFOLDS. :13-25.
Coste B.  2014.  Algernon Charles Swinburne and the post-romantic issues of creation. CAHIERS VICTORIENS & EDOUARDIENS.

Pages